Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome KATP Channel Mutations in Intact Cells

Gain-of-function of KATP channels, resulting from mutations in either KCNJ8 (encoding inward rectifier sub-family 6 [Kir6.1]) or ABCC9 (encoding sulphonylurea receptor [SUR2]), cause Cantú syndrome (CS), a channelopathy characterized by excess hair growth, coarse facial appearance, cardiomegaly, and lymphedema. Here, we established a pipeline for rapid analysis of CS mutation consequences in Landing pad HEK 293 cell lines stably expressing wild type (WT) and mutant human Kir6.1 and SUR2B. Thallium-influx and cell membrane potential, reported by fluorescent Tl-sensitive Fluozin-2 and voltage-sensitive bis-(1,3-dibutylbarbituric acid)trimethine oxonol (DiBAC4(3)) dyes, respectively, were used to assess channel activity. In the Tl-influx assay, CS-associated Kir6.1 mutations increased sensitivity to the ATP-sensitive potassium (KATP) channel activator, pinacidil, but there was strikingly little effect of pinacidil for any SUR2B mutations, reflecting unexpected differences in the molecular mechanisms of Kir6.1 versus SUR2B mutations. Compared with the Tl-influx assay, the DiBAC4(3) assay presents more significant signal changes in response to subtle KATP channel activity changes, and all CS mutants (both Kir6.1 and SUR2B), but not WT channels, caused marked hyperpolarization, demonstrating that all mutants were activated under ambient conditions in intact cells. Most SUR2 CS mutations were markedly inhibited by <100 nM glibenclamide, but sensitivity to inhibition by glibenclamide, repaglinide, and PNU37883A was markedly reduced for Kir6.1 CS mutations. Understanding functional consequences of mutations can help with disease diagnosis and treatment. The analysis pipeline we have developed has the potential to rapidly identify mutational consequences, aiding future CS diagnosis, drug discovery, and individualization of treatment. SIGNIFICANCE STATEMENT We have developed new fluorescence-based assays of channel activities and drug sensitivities of Cantú syndrome (CS) mutations in human Kir6.1/SUR2B-dependent KATP channels, showing that Kir6.1 mutations increase sensitivity to potassium channel openers, while SUR2B mutations markedly reduce K channel opener (KCO) sensitivity. However, both Kir6.1 and SUR2B CS mutations are both more hyperpolarized than WT cells under basal conditions, confirming pathophysiologically relevant gain-of-function, validating DiBAC4(3) fluorescence to characterize hyperpolarization induced by KATP channel activity under basal, non KCO-activated conditions.

[1]  C. Nichols,et al.  A Unique High‐Output Cardiac Hypertrophy Phenotype Arising From Low Systemic Vascular Resistance in Cantu Syndrome , 2022, Journal of the American Heart Association.

[2]  C. Nichols,et al.  Lymphedema as first clinical presentation of Cantu Syndrome: reversed phenotyping after identification of gain-of-function variant in ABCC9 , 2022, European Journal of Human Genetics.

[3]  C. Nichols Personalized Therapeutics for KATP-Dependent Pathologies. , 2022, Annual Review of Pharmacology and Toxicology.

[4]  David Nedrud,et al.  Determinants of trafficking, conduction, and disease within a K+ channel revealed through multiparametric deep mutational scanning , 2022, bioRxiv.

[5]  C. Nichols,et al.  ATP-sensitive potassium channels in zebrafish cardiac and vascular smooth muscle. , 2021, The Journal of physiology.

[6]  C. Nichols,et al.  Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome , 2021, Cells.

[7]  John D. Russo,et al.  Vascular KATP channel structural dynamics reveal regulatory mechanism by Mg-nucleotides , 2021, Proceedings of the National Academy of Sciences.

[8]  C. Nichols,et al.  Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome , 2020, Frontiers in Pharmacology.

[9]  Hongzhen Hu,et al.  Kir6.1- and SUR2-dependent KATP overactivity disrupts intestinal motility in murine models of Cantú syndrome , 2020, JCI insight.

[10]  F. Ashcroft,et al.  Evaluating inositol phospholipid interactions with inward rectifier potassium channels and characterising their role in disease , 2020, bioRxiv.

[11]  B. Zinselmeyer,et al.  Kir6.1‐dependent KATP channels in lymphatic smooth muscle and vessel dysfunction in mice with Kir6.1 gain‐of‐function , 2020, The Journal of physiology.

[12]  T. Cardozo,et al.  Palmitoylation of the KATP channel Kir6.2 subunit promotes channel opening by regulating PIP2 sensitivity , 2020, Proceedings of the National Academy of Sciences.

[13]  M. Itoh,et al.  A novel mutation in the KCNJ8 gene encoding the Kir6.1 subunit of an ATP‐sensitive potassium channel in a Japanese patient with Cantú syndrome , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  C. Nichols,et al.  The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome , 2020, Function.

[15]  C. Nichols,et al.  Glibenclamide reverses cardiovascular abnormalities of Cantu Syndrome driven by KATP channel overactivity. , 2019, The Journal of clinical investigation.

[16]  Kenneth A. Matreyek,et al.  An improved platform for functional assessment of large protein libraries in mammalian cells , 2019, Nucleic acids research.

[17]  T. Roscioli,et al.  Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain‐of‐function variant: Initial experience , 2019, American journal of medical genetics. Part A.

[18]  M. A. van der Heyden,et al.  Glibenclamide and HMR1098 normalize Cantú syndrome‐associated gain‐of‐function currents , 2019, Journal of cellular and molecular medicine.

[19]  A. Tinker,et al.  ATP-Sensitive Potassium Channels and Their Physiological and Pathophysiological Roles. , 2018, Comprehensive Physiology.

[20]  Yan Huang,et al.  Cardiovascular consequences of KATP overactivity in Cantu syndrome. , 2018, JCI insight.

[21]  C. Nichols,et al.  Cantu syndrome–associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms , 2017, The Journal of Biological Chemistry.

[22]  C. Yoshioka,et al.  Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM , 2017, eLife.

[23]  C. Nichols,et al.  Conserved functional consequences of disease-associated mutations in the slide helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel , 2017, The Journal of Biological Chemistry.

[24]  Kenneth A. Matreyek,et al.  A platform for functional assessment of large variant libraries in mammalian cells , 2017, Nucleic acids research.

[25]  N. Gao,et al.  Structure of a Pancreatic ATP-Sensitive Potassium Channel , 2017, Cell.

[26]  James Z. Chen,et al.  Cryo-EM structure of the ATP-sensitive potassium channel illuminates mechanisms of assembly and gating , 2016, bioRxiv.

[27]  C. Nichols,et al.  The shifting landscape of KATP channelopathies and the need for 'sharper' therapeutics. , 2016, Future medicinal chemistry.

[28]  W. Cui,et al.  Sensitivity of KATP channels to cellular metabolic disorders and the underlying structural basis , 2016, Acta Pharmacologica Sinica.

[29]  C. Nichols,et al.  Differential mechanisms of Cantú syndrome–associated gain of function mutations in the ABCC9 (SUR2) subunit of the KATP channel , 2015, The Journal of general physiology.

[30]  A. Wojtovich,et al.  Direct Activation of β-Cell KATP Channels with a Novel Xanthine Derivative , 2014, Molecular Pharmacology.

[31]  Meghan C Towne,et al.  Mutation of KCNJ8 in a patient with Cantú syndrome with unique vascular abnormalities - support for the role of K(ATP) channels in this condition. , 2013, European journal of medical genetics.

[32]  Anlong Li,et al.  Hypotension Due to Kir6.1 Gain‐of‐Function in Vascular Smooth Muscle , 2013, Journal of the American Heart Association.

[33]  K. Nanjo,et al.  Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus , 2013, Journal of diabetes investigation.

[34]  C. Weaver,et al.  High-throughput screening for small-molecule modulators of inward rectifier potassium channels. , 2013, Journal of visualized experiments : JoVE.

[35]  Stef van Lieshout,et al.  Dominant missense mutations in ABCC9 cause Cantú syndrome , 2012, Nature Genetics.

[36]  T. Flagg,et al.  Muscle KATP channels: recent insights to energy sensing and myoprotection. , 2010, Physiological reviews.

[37]  D. Wilson Tissue , 2009, The Lancet.

[38]  N. Cui,et al.  PKA phosphorylation of SUR2B subunit underscores vascular KATP channel activation by beta-adrenergic receptors. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[39]  R. Scharfmann,et al.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. , 2006, The New England journal of medicine.

[40]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[41]  F. Cerutti,et al.  Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene , 2006, Diabetologia.

[42]  Colin G. Nichols,et al.  KATP channels as molecular sensors of cellular metabolism , 2006, Nature.

[43]  J. Haynes,et al.  Protein kinase G‐induced activation of KATP channels reduces contractility of human prostate tissue , 2006, The Prostate.

[44]  T. Tomoda,et al.  Different glibenclamide-sensitivity of ATP-sensitive K+ currents using different patch-clamp recording methods. , 2006, European journal of pharmacology.

[45]  C. Nichols,et al.  ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy. , 2005, Diabetes.

[46]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[47]  W. Giles,et al.  Pharmacological activation of plasma‐membrane KATP channels reduces reoxygenation‐induced Ca2+ overload in cardiac myocytes via modulation of the diastolic membrane potential , 2004, British journal of pharmacology.

[48]  T. Kamishima,et al.  Molecular analysis of the subtype‐selective inhibition of cloned KATP channels by PNU‐37883A , 2004, British journal of pharmacology.

[49]  M. Vornanen,et al.  The induction of an ATP-sensitive K+ current in cardiac myocytes of air- and water-breathing vertebrates , 2002, Pflügers Archiv.

[50]  H. Huopio,et al.  K(ATP) channels and insulin secretion disorders. , 2002, American journal of physiology. Endocrinology and metabolism.

[51]  K. Muraki,et al.  Usefulness and limitation of DiBAC4(3), a voltage-sensitive fluorescent dye, for the measurement of membrane potentials regulated by recombinant large conductance Ca2+-activated K+ channels in HEK293 cells. , 2001, Japanese journal of pharmacology.

[52]  C. Nichols,et al.  ATP interaction with the open state of the K(ATP) channel. , 2001, Biophysical journal.

[53]  F. Ashcroft,et al.  Differential response of K(ATP) channels containing SUR2A or SUR2B subunits to nucleotides and pinacidil. , 2000, Molecular pharmacology.

[54]  S. Yamashita,et al.  C-Terminal Tails of Sulfonylurea Receptors Control ADP-Induced Activation and Diazoxide Modulation of ATP-Sensitive K+ Channels , 2000, Circulation research.

[55]  U. Panten,et al.  Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes , 1999, British journal of pharmacology.

[56]  I. Uhde,et al.  Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. , 1999, Molecular pharmacology.

[57]  Y. Horio,et al.  ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP. , 1999, Molecular pharmacology.

[58]  J. Sullivan,et al.  Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[59]  F. Ashcroft,et al.  Molecular Analysis of ATP-sensitive K Channel Gating and Implications for Channel Inhibition by ATP , 1998, The Journal of general physiology.

[60]  Y. Horio,et al.  SUR2 subtype (A and B)‐dependent differential activation of the cloned ATP‐sensitive K+ channels by pinacidil and nicorandil , 1998, British journal of pharmacology.

[61]  U. Quast,et al.  Binding of KATP channel modulators in rat cardiac membranes , 1998, British journal of pharmacology.

[62]  P. Rorsman,et al.  Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. , 1998, Diabetes.

[63]  C. Nichols,et al.  Octameric Stoichiometry of the KATP Channel Complex , 1997, The Journal of general physiology.

[64]  F. Ashcroft,et al.  The Interaction of nucleotides with the tolbutamide block of cloned atp‐sensitive k+ channel currents expressed in xenopus oocytes: a reinterpretation , 1997, The Journal of physiology.

[65]  F. Ashcroft,et al.  Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor , 1997, Nature.

[66]  Y. Horio,et al.  Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea‐sensitive but ATP‐insensitive K+ channel. , 1997, The Journal of physiology.

[67]  Y. Horio,et al.  A Novel Sulfonylurea Receptor Forms with BIR (Kir6.2) a Smooth Muscle Type ATP-sensitive K+ Channel* , 1996, The Journal of Biological Chemistry.

[68]  M. L. Le Beau,et al.  Cloning, Tissue Expression, and Chromosomal Localization of SUR2, the Putative Drug-Binding Subunit of Cardiac, Skeletal Muscle, and Vascular KATP Channels , 1996, Diabetes.

[69]  M. Permutt,et al.  Adenosine Diphosphate as an Intracellular Regulator of Insulin Secretion , 1996, Science.

[70]  J. K. Gibson,et al.  Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines. , 1996, Methods and Findings in Experimental and Clinical Pharmacology.

[71]  J. Inazawa,et al.  Reconstitution of IKATP: An Inward Rectifier Subunit Plus the Sulfonylurea Receptor , 1995, Science.

[72]  P. Manley,et al.  Binding of the K+ channel opener [3H]P1075 in rat isolated aorta: relationship to functional effects of openers and blockers. , 1993, Molecular pharmacology.

[73]  C F Stevens,et al.  Inferences about membrane properties from electrical noise measurements. , 1972, Biophysical journal.

[74]  W. Coetzee,et al.  KATP Channels in the Cardiovascular System. , 2016, Physiological reviews.

[75]  Daling Zhu,et al.  PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery. , 2008, Biochimica et biophysica acta.

[76]  N. Cui,et al.  PKA phosphorylation of SUR 2 B subunit underscores vascular KATP channel activation by beta-adrenergic receptors , 2007 .

[77]  I. So,et al.  ATP-sensitive K(+) channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[78]  J. Koster,et al.  Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. , 2000, Cell.

[79]  C. Nichols,et al.  Sulfonylurea and K(+)-channel opener sensitivity of K(ATP) channels. Functional coupling of Kir6.2 and SUR1 subunits. , 1999, The Journal of general physiology.

[80]  K. Kunjilwar,et al.  Toward understanding the assembly and structure of KATP channels. , 1998, Physiological reviews.